SCHEMBL4467113

SCHEMBL4467113

CSc1ccc(Oc2ccc(C(C)=O)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.73
MAPT P10636 4/20 0.73
RAB9A P51151 2/20 0.73
LMNA P02545 4/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
ESRRA P11474 1/20 0.49
ALDH1A1 P00352 4/20 0.48
PLK1 P53350 1/20 0.48
NPSR1 Q6W5P4 3/20 0.47
GAA P10253 1/20 0.47
STS P08842 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
TSHR P16473 1/20 0.46
HTT P42858 1/20 0.46
PARP10 Q53GL7 2/20 0.45
KMT2A Q03164 1/20 0.45
PARP15 Q460N3 1/20 0.45
PARP14 Q460N5 1/20 0.45
PARP16 Q8N5Y8 1/20 0.45
PARP11 Q9NR21 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL195321 0.88 HPGD (0.70) HPGDMAPTRAB9ALMNAL3MBTL1
SCHEMBL203697 0.85 HPGD (1.00) HPGDMAPTRAB9ALMNAL3MBTL1
SCHEMBL3301210 0.85 HPGD (1.00) HPGDMAPTRAB9ALMNAL3MBTL1
SCHEMBL2731286 0.85 PARP15 (0.58) HPGDMAPTRAB9AALDH1A1PLK1
SCHEMBL9389572 0.83 PARP10 (0.70) HPGDMAPTRAB9AALDH1A1PLK1
SCHEMBL13255077 0.82 RAB9A (0.49) HPGDMAPTRAB9ALMNAL3MBTL1
SCHEMBL10871476 0.82 HPGD (0.83) HPGDMAPTRAB9ALMNAL3MBTL1
SCHEMBL10871366 0.82 HPGD (0.61) HPGDMAPTRAB9ALMNAL3MBTL1
SCHEMBL10870869 0.82 HPGD (0.61) HPGDMAPTRAB9ALMNAL3MBTL1
SCHEMBL25364064 0.81 CA1 (0.58) HPGDMAPTRAB9ALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed
EP-0192167-A1 Use of thio-substitued ketones as photoinitiators MERCK PATENT GmbH (DE) 1986-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 HPGD 303/4885MAPT 2398/4885RAB9A 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.